Ibogaine List Archives – 2005-05

Howard Lotsof

From: tink <tinkerbell.sarah@gmail.com> Subject: Re: [Ibogaine] Vascular Trouble Date: June 1, 2005 at 12:16:24 AM EDT To: ibogaine@mindvox.com Reply-To: ibogaine@mindvox.com thankyou for that clarity.  We never would’ve figured it out. :] tink(sick fux inc) On 5/31/05, Schmoolyboy@aol.com <Schmoolyboy@aol.com> wrote: The Fang are also not tweeked sick junkies who abused their…

Continue reading

Ibogaine List Archives – 2004-10

MindVox Corporation

From: HSLotsof@aol.com Subject: Re: [Ibogaine] Carla, re: George Bush, the fascist capitalist dictator from Texas Date: October 31, 2004 at 9:07:14 PM EST To: ibogaine@mindvox.com Reply-To: ibogaine@mindvox.com Ibogaine is not a cure.  It is a highly effective treatment.  It is about as good as it gets unless you opt for…

Continue reading

Ibogaine List Archives – 2004-06

MindVox Corporation

From: CrookedEye420@aol.com Subject: Re: [ibogaine] Sara’s web site down?help needed Date: June 30, 2004 at 11:56:50 PM EDT To: ibogaine@mindvox.com Reply-To: ibogaine@mindvox.com In a message dated 6/24/2004 12:11:42 AM Eastern Daylight Time, HSLotsof@aol.com writes: The web page is missing as are the search engine citations.  There used to be a…

Continue reading

Ibogaine Patents @ the USPO

Ibogaine Patents @ the United States Patent Office (USPO) Use of ibogaine in reducing excitotoxic brain damage Use of ibogaine in reducing excitotoxic brain damage This invention discloses that ibogaine, a plant derivative, can be used as a safe NMDA antagonist at relatively high dosages (including dosages high enough to…

Continue reading

Ibogaine Abstracts on PubMed

18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. 18-MC, a novel iboga alkaloid congener, is being developed as a potential treatment for multiple forms of drug abuse. Like ibogaine (40 mg/kg), 18-MC…

Continue reading

Uncovering Ibogaine

the Deborah Mash Interview with Paul DeRienzo Dr. Deborah Mash is a faculty member in the Department of Neurology of the University of Miami, School of Medicine with a secondary appointment in Cellular Molecular Pharmacology. Dr. Mash’s area of expertise is called Neuropharmacology and Neuroscience and her doctoral dissertation was…

Continue reading

Ibogaine: A Novel Anti-Addictive Compound…

Ibogaine: A Novel Anti-Addictive Compound A Comprehensive Literature Review By: Jonathan Freedlander Advisor: Carlo DiClemente, Ph.D. University of Maryland, Baltimore County Introduction and History Ibogaine is a naturally occurring indole alkaloid, found in a variety of African shrubs of the Tabernanthe genus (Obach, Pablo, and Mash, 1998). The root of…

Continue reading

Ibogaine in the 21st Century: Boosters, Tune-ups and Maintenance

maps • volume xv number 1 • Spring 2005 By Patrick K. Kroupa & Hattie Wells History The history of using ibogaine to break the cycle of drug-dependence is relatively short. While it is likely that the CIBA pharmaceutical company and the US government were aware of ibogaine’s anti-addictive properties…

Continue reading

Ibogaine: Complex Pharmacokinetics…

Reprinted from Neurobiological Mechanisms of Drugs of Abuse Volume 914 of the Annals of the New York Academy of Sciences September 2000 Ibogaine: Complex Pharmacokinetics, Concerns for Safety, and Preliminary Efficacy Measures DEBORAH C. MASH,[a,b,h] CRAIG A. KOVERA,[o] JOHN PABLO,[o] RACHEL F. TYNDALE,[c] FRANK D. ERVIN,[d] IZBEN C. WILLIAMS,[e] EDWARD…

Continue reading